A novel inflammatory marker for extensive ulcerative colitis; Endocan

Abstract

Background & aims Ulcerative colitis (UC) is an inflammatory bowel disease characterized by mucosal inflammation. Endocan, a proteoglycan secreted by endothelial cells in response to inflammatory cytokines, has been reported to be overexpressed in inflammatory conditions. In this study, we aimed to evaluate the utility of endocan level in determining the extent and severity of disease in patients with ulcerative colitis and to determine whether it can be a candidate marker for noninvasive evaluation and monitoring since there is not enough data in the literature. Materials and methods Sixty-five people were included in the study, including thirty-five with ulcerative colitis and thirty in the control group. Patients with first diagnosed ulcerative colitis clinically, endoscopically, and histopathologically, without any treatment, and with normal liver and kidney tests were included in the study. Endoscopic scoring of all patients was performed according to the Mayo endoscopic scoring (MES) system. Blood samples for CRP (C-reactive protein) and endocan were taken from the patients simultaneously. Results There was a significant statistical difference between all patients with ulcerative colitis and the control group in both endocan level and CRP level (p < 0.001). There was a statistically significant difference between endocan levels and CRP levels between the left-distal group and pancolitis (diffuse colitis) patients, but there was no statistical difference between age and MES. Conclusion Serum endocan level can be useful in determining the extent of ulcerative colitis and planning treatment.

Relationship between salusin beta levels and the severity of acute pancreatitis in patients

“…In a study by Albayrak et al, endocan levels, secreted by endothelial cells in response to inflammatory cytokines, were shown to be useful in determining the prevalence of ulcerative colitis characterized by mucosal inflammation and could be beneficial in treatment planning. [23,24] Elevated levels of endocan, similar to SAL-β, were found in both patients with AP and severe ulcerative colitis, aligned with the design of our study. Ultimately, biomarkers identified as elevated in severe pancreatitis can be used for prognosis monitoring and assist clinicians.…”

The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan’s National Health Insurance Research Database

“…Another important finding in this report is that the young adult colchicine users were associated with the lower aHR of colorectal cancer among the IMIDs [ 21 , 47 ].…”

“…The patients who used colchicine between 2000 and 2012 were defined as colchicine users among patients with IMIDs ( N = 23,612) [ 6 – 8 , 20 , 21 ]. The colchicine users need to fulfill criteria as below: in Lin et al’s study, the nude mice experiment showed that colchicine-treated mice after 14 days of treatment had lower increased tumor volume ratios and tumor growth rates than the control.…”

“…Excluding criteria ( N = 1148) in colchicine users as below: not Taiwanese citizens, or aged < 20 years, had no IMIDs-related prescription requirements or related management or procedure 1 year after the first IMIDs diagnosis; had a disease history of IMIDs or received colchicine before the first IMIDs diagnosis or previous history of cancer ( ICD-9-CM codes 140–239) [ 7 , 21 , 24 ]. The colchicine may be considered as an immunosuppressant agent, and the colchicine may interact with other immunosuppressant.…”